SCHEMBL16044648

SCHEMBL16044648

C[C@H](N)c1cccc(OC(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.41
PTGS1 P23219 1/20 0.40
KCNK2 O95069 1/20 0.38
KCNA5 P22460 1/20 0.38
KCNH2 Q12809 1/20 0.38
KCNB1 Q14721 1/20 0.38
ALOX5 P09917 1/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
MEN1 O00255 3/20 0.37
MAPT P10636 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
ACHE P22303 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
SENP8 Q96LD8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19876580 1.00 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
SCHEMBL4230419 1.00 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
Hydrochloric Acid SCHEMBL21272664 0.98 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
Hydrochloric Acid SCHEMBL30117134 0.98 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
Hydrochloric Acid SCHEMBL21272665 0.98 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
Hydrochloric Acid SCHEMBL30117168 0.98 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
Hydrochloric Acid SCHEMBL29440457 0.98 DRD1 (0.41) DRD1PTGS1KCNK2KCNA5KCNH2
SCHEMBL14122063 0.85 RXRA (0.44) PTGS1ALOX5MEN1KMT2ASMN1; SMN2
SCHEMBL824148 0.85 KDM4E (0.46) DRD1PTGS1KCNK2KCNA5KCNH2
SCHEMBL14157496 0.85 RXRA (0.44) PTGS1ALOX5MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12508239-B2 Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures H. LUNDBECK A/S (DK) 2025-12-30 US disclosed
EP-4007571-B1 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES H LUNDBECK AS (DK) 2025-06-18 EP disclosed
EP-4241843-B1 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS H LUNDBECK AS (DK) 2025-05-21 EP disclosed
US-12258305-B2 Alcohol derivatives as Kv7 potassium channel openers H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-119490430-A Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures H.隆德贝克有限公司 2025-02-21 CN disclosed
CN-114206328-B Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures H.隆德贝克有限公司 2024-09-17 CN disclosed
EP-4241843-A2 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS H. Lundbeck A/S (DK) 2023-09-13 EP disclosed
EP-4241843-A2 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS H. Lundbeck A/S (DK) 2023-09-13 EP disclosed
CN-116589375-A Alcohol derivatives as Kv7 potassium channel openers H.隆德贝克有限公司 2023-08-15 CN disclosed
EP-3755684-B1 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS H LUNDBECK AS (DK) 2023-07-12 EP disclosed
US-20160318915-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2016-11-03 US disclosed
US-9434719-B2 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH NOVARTIS AG (CH) 2016-09-06 US disclosed
US-9434719-B2 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH NOVARTIS AG (CH) 2016-09-06 US disclosed
US-9434719-B2 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH NOVARTIS AG (CH) 2016-09-06 US disclosed
US-20150152093-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2015-06-04 US disclosed
US-20150152093-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2015-06-04 US disclosed
US-20150152093-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2015-06-04 US disclosed
US-20140275083-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2014-09-18 US disclosed
US-20140275083-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2014-09-18 US disclosed
US-20140275083-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275083-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH IDH1, IDH3B, IDH3A DRD1 2580/4885PTGS1 2012/4885KCNK2 1469/4885
US-20160318915-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH IDH1, IDH3B, IDH3A DRD1 2580/4885PTGS1 2012/4885KCNK2 1469/4885
US-20150152093-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH IDH1, IDH3B, IDH3A DRD1 2580/4885PTGS1 2012/4885KCNK2 1469/4885
US-12508239-B2 Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures KCNN3, KCNN1, KCNN2 DRD1 2516/4885PTGS1 3171/4885KCNK2 20/4885
US-12258305-B2 Alcohol derivatives as Kv7 potassium channel openers KCNA7, KCNK17, KCNQ1 DRD1 1067/4885PTGS1 2958/4885KCNK2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.